Loading...
XSHE
300584
Market cap605mUSD
Oct 09, Last price  
33.52CNY
1D
-0.83%
1Q
-2.59%
IPO
185.68%
Name

Nanjing Hicin Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XSHE:300584 chart
P/E
95.64
P/S
5.99
EPS
0.35
Div yield, %
0.30%
Shrs. gr., 5y
—
Rev. gr., 5y
3.02%
Revenues
671m
+33.05%
147,952,995169,502,080197,655,206220,993,472280,827,570455,034,584711,907,832924,537,939706,295,709578,315,038578,315,038526,465,340526,465,339517,832,190504,360,393671,048,953
Net income
42m
+4.58%
25,592,00933,287,34334,214,07840,328,96345,236,37865,600,50683,223,21797,258,21355,230,056285,878,182285,878,18932,448,86732,448,87036,315,55840,217,91342,058,385
CFO
78m
+30.24%
38,767,53845,164,66524,293,22753,902,47537,737,79046,557,48177,210,75497,277,03973,388,59359,940,771023,932,69259,960,14178,089,132
Dividend
Jun 25, 20260.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Nanjing Hicin Pharmaceutical Co., Ltd. (NHPC), established in 2003 and headquartered in Nanjing, China, operates as a comprehensive enterprise specializing in the research, development, production, marketing, and distribution of pharmaceutical preparations and synthetic chemicals within China. The company boasts a diverse product portfolio, addressing various therapeutic areas such as antivirals, antibiotics, endocrine regulators, gastrointestinal treatments, orthopedic medications, cardiovascular and cerebrovascular drugs, and immunomodulatory agents. Beyond its core pharmaceutical activities, NHPC also provides technology transfer services. On an international scale, Nanjing Hicin Pharmaceutical Co., Ltd. is a supplier of Active Pharmaceutical Ingredients (APIs). Its export offerings specifically include injectable forms of omeprazole sodium and cefepime hydrochloride, along with lansoprazole tablets, which reach markets across South Asia, South America, and Europe.

Key people

Yuping Cao
Chairman of the Board, General Manager · since 2003
Jianren Chen
Chief Financial Officer · since 2022
Guangyao Liu
Deputy General Manager · since 2024
Jin Lu
Secretary of the Board, Deputy General Manager · since 2019
Weibiao Yue
Deputy General Manager · since 2022
Li Wang
Deputy General Manager, Secretary of the Board · since 2022
Xichen Cao
Director · since 2022
Yuanhong Chu
Staff Elected Director · since 2025
Mingsheng Feng
Director · since 2022
Independent Director · since 2025
Lingxiao Mao
Independent Director · since 2023
Ming Zhao
Independent Director · since 2019
IPO date
Jan 12, 2017
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
南京经济技术开发区恒发路1号
南京市, JS 210000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT